Skip to main content

Table 2 Outline of trial visits

From: Treating nightmares in posttraumatic stress disorder with dronabinol: study protocol of a multicenter randomized controlled study (THC PTSD-trial)

Assessments

SC

BL

Visit 1

W 0

Visit 2

W 1

Visit 3

W 2

Visit 4

W 3

Visit 5

W 4

Visit 6

W 6

Visit 7

W 8

Visit 8

W 10

FU

Visit 9

W 12

Screening and consent

 Inclusion/exclusion criteria

X

         

 Informed consent

X

         

 Physical examination1

X

       

X

 

 Prior and concomitant medi-cation and non-drug therapy

X

X

X

X

X

X

X

X

X

X

 Medical history

X

         

 IMP dispersion

 

X

X

X

X

X

X

X

  

 IMP return

  

X

X

X

X

X

X

X

 

Safety

 Blood test2

X

       

X

 

 Cannabis test

X

         

 Pregnancy test

X

X

 

X

 

X

X

X

X

 

 ECG

X

       

X

(X)3

 Blood pressure, pulse

X

X

X

X

X

X

X

X

X

X

 Weight

X

X

    

X

 

X

X

 Adverse event recording

 

X

X

X

X

X

X

X

X

X

Effectiveness

 Primary

  CAPS-IV B2

        

X

 

 Secondary

  CAPS-IV B2

X

X

X

X

X

X

X

X

  

  CAPS-5

Xa

Xb

    

Xb

 

Xb

 

  PSQI-A

 

X

    

X

 

X

 

  MADRS

X

X

   

X

  

X

 

  Sleep diary

 

X

X

X

X

X

X

X

X

 

  PCL-5

 

X

    

X

 

X

 

  BSL-23

 

X

    

X

 

X

 

  EQ-5D

 

X

    

X

 

X

 

  PGIC

      

X

 

X

 

  SOFAS

 

X

    

X

 

X

 

  PSQI

 

X

    

X

 

X

 

  ITQ

 

X

    

X

 

X

 

  MWC

 

X

    

X

 

X

X

 Others

  Demographics

X

         

  CTQ

X

         

  MINI-5

X

         

  ITI

X

         
  1. SC Screening, W. week ± 3 days, BL Baseline and randomization, FU Post-trial follow-up, CAPS-IV B2 B2 score of the Clinician-Administered PTSD Scale for DSM-IV (frequency and intensity of nightmares), CAPS-5 Clinician-Administered PTSD Scale for DSM-5 (a = last month version, b = last week version), PSQI-A Pittsburgh Sleep Quality Index-Addendum for PTSD, MADRS Montgomery–Åsberg Depression Rating Scale, PCL-5 PTSD Checklist for DSM-5, BSL-23 Borderline Symptom List 23, EQ-5D Health-Related Quality of Life, PGIC Patient Global Impression of Change, SOFAS Social and Occupational Functioning Assessment Scale, PSQI Pittsburgh Sleep Quality Index, ITQ International trauma questionnaire, MWC Marijuana Withdrawal Checklist, CTQ Childhood trauma questionnaire, MINI-5 The Mini International Neuropsychiatric Interview for DSM-5, ITI International Trauma Interview
  2. 1Physical examination includes height and weight of the patient and the skin, abdomen, respiratory system, head and extremities will be examined
  3. 2blood test s include haematology (erythrocytes, haemoglobin, haematocrit, platelets, leukocytes (including neutrophils, eosinophils, basophils, lymphocytes, monocytes) and serum chemistry (sodium, potassium, chloride, calcium, creatinine, alanine aminotransferase, alkaline phosphatase, gamma glutamyl transferase, aspartate aminotransferase, bilirubin, lipase, thyroid stimulating hormone)
  4. 3In case of significant abnormal ECG findings at the visit 8 (week 10), a further ECG will be recorded at the follow-up visit
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us